Market research
ORGS Orgenesis Inc
PINK USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 556K
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 2.87
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 556K
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 2.87
About
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Research context
Orgenesis Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ORGS discussion.
5 years, 6 months ago
Orgenesis Inc is currently in a long term downtrend where the price is trading 12.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.1.
Orgenesis Inc's total revenue sank by 74.7% to $2M since the same quarter in the previous year.
Its net income has dropped by 751.7% to $-52M since the same quarter in the previous year.
Finally, its free cash flow fell by 421.7% to $-45M since the same quarter in the previous year.
Based on the above factors, Orgenesis Inc gets an overall score of 1/5.